Axisresearch
List of Categories
- Aerospace & Defense
- Agriculture
- Animal Nutrition & Wellness
- Automation
- Automotive
- Chemical & Materials
- Consumer Goods and Services
- Electronics
- Energy & Mining
- Financial Services & Investment Intelligence
- Food & Beverage
- Healthcare
- Heavy Industry
- Home & Property Improvement
- Information & Communications Technology
- Investment Opportunities
- Manufacturing
- NEO
- Others
- Packaging
- Retail
- Technology & Media
- Transportation & Logistics
Sorted by Name
Publishers
Countries
Sleep Apnea Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 116 pages | Published: 24-06-2019 |
- Healthcare
- Mordor Intelligence
- 116 pages
- Published: 24-06-2019
Market Overview
The global sleep apnea devices market was valued at USD 5,956.9 million in 2018, and is estimated to be valued at USD 9,193.3 million in 2024, witnessing a CAGR of 7.5%. Few key factors that are driving the market include the increasing incidences of sleep apnea, increasing awareness among the patient population in developing countries, and favorable government initiatives.
According to the Sleep Apnea Organization, in 2017, more than 22 million Americans suffered from sleep apnea and 80% of moderate to severe sleep apnea cases were undiagnosed; worldwide, over 100 million people suffer from sleep apnea. Thus, the increasing incidence of sleep apnea is one of the factors responsible for the growth of the sleep apnea devices market.
It is known that obstructive sleep apnea (OSA) is a prevalent condition, which affects up to 20% of the world population. It is a serious and life-threatening sleep illness that is largely undiagnosed and untreated. However, various government initiatives are helping patients who suffer from OSA. For instance, in the United States, the American Sleep Apnea Association (ASAA) was founded in 1990, which is a non-profit organization that promotes awareness regarding sleep apnea, works for continuing improvements in treatments for this serious disorder, and advocates for the interests of sleep apnea patients. All these factors are boosting the market.
Scope of the Report
Sleep apnea is a serious sleep disorder, in which breathing repeatedly stops and starts. There are three main types of sleep apnea, obstructive sleep apnea, central sleep apnea, and complex sleep apnea syndrome. The factors, such as increased incidences of sleep apnea, increasing awareness among the patient population in the developing countries, favorable government initiatives, and upcoming technological advancements, are expected to drive the growth of the market over the forecast period.
Key Market Trends
Actigraphy Devices is Expected to Grow with Highest CAGR in the Diagnostic Devices Category
Actigraphy devices (actometer or actimeter) utilize a portable device, which is usually worn on the wrist that records physical movement over an extended period. This technology is being increasingly adopted in clinical settings, as actigraphy has the advantage of providing objective information on the sleep habits in patients’ natural sleep environment.
Since actigraphy is less invasive and less expensive than the PSG devices, it is a promising device for assessing sleep apnea treatment effects. It also can be used for follow-up, once the treatment has begun or to evaluate changes in sleep, over the course of the treatment period. The rising demand for actigraphy devices in sleep apnea is due to its cost effectiveness, as it facilitates non-intrusive 24-hours monitoring at home for extended periods. The sleep-wake is relatively easy and it does not require any installation.
North America Dominates the Market and Expected to continue its Dominance through the Forecast Period
North America currently dominates the market for sleep apnea devices and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future, owing to the high incidence of sleep-disordered breathing (SDB) and rising aging population in the region. The United States holds the majority of the market in the North American region. According to the American Sleep Association, as of 2018, it was estimated that about 50-70 million adult population in the United States were found to have a sleep disorder, 48% were reported to be snoring, 37.9% were reported to be falling asleep during the day, unintentionally, and 4.7% were reported to be nodding off while driving. Insomnia is the most common specific sleep disorder, with short-term issues reported by about 30% of adults and chronic insomnia by 10%. Approximately 25 million adults in the United States have obstructive sleep apnea.
According to Sleep Zone, it was estimated that about 22 million Americans suffer from moderate to severe sleep apnea, out of which, approximately 3-7% of men and 2-5% of women were found to have had sleep apnea in 2018 in the United States.
Competitive Landscape
The sleep apnea devices market is highly competitive and consists of several major player, across the world. Further, with rising technological advancements and product innovations, mid-size and small scale companies are increasing their market presence by introducing new devices into the market with competitive prices. Companies, like Resmed, Fisher & Paykel Healthcare Limited, and Invacare Corporation, hold substantial shares in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Incidences of Sleep Apnea
4.2.2 Increasing Awareness Among the Patient Population in the Developing Countries
4.2.3 Favorable Government Initiatives
4.2.4 Upcoming Technological Advancements
4.3 Market Restraints
4.4 Industry Attractiveness- Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Diagnostic Devices
5.1.1 Polysomnography Devices (PSG)
5.1.2 Pulse Oximeters
5.1.3 Actigraphy Devices
5.2 By Therapeutic Devices
5.2.1 Positive Airway Pressure (PAP) Devices
5.2.1.1 Continuous Positive Airway Pressure (CPAP) Devices
5.2.1.2 Bi-level Positive Airway Pressure (BiPAP) Devices
5.2.2 Oxygen Devices
5.2.2.1 Oxygen Concentrators
5.2.2.2 Portable Oxygen Concentrators
5.2.2.3 Liquid Portable Oxygen
5.2.3 Oral Appliances
5.2.4 Adaptive Servo Ventilation (ASV) Devices
5.2.5 Masks and Accessories
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 South America
5.3.4.1 Brazil
5.3.4.2 Argentina
5.3.4.3 Rest of South America
5.3.5 Middle East & Africa
5.3.5.1 GCC
5.3.5.2 South Africa
5.3.5.3 Rest of Middle East & Africa
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Fisher & Paykel Healthcare Limited
6.1.2 Koninklijke Philips NV
6.1.3 Invacare Corporation
6.1.4 Natus Medical Incorporated
6.1.5 Resmed
6.1.6 Cadwell Laboratories Inc.
6.1.7 Vyaire Medical Inc.
6.1.8 GE Healthcare
6.1.9 Nihon Kohden Corporation
6.1.10 Teleflex Incorporated
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Diagnostic Devices
Polysomnography Devices (PSG)
Pulse Oximeters
Actigraphy Devices
By Therapeutic Devices
Positive Airway Pressure (PAP) Devices
Continuous Positive Airway Pressure (CPAP) Devices
Bi-level Positive Airway Pressure (BiPAP) Devices
Oxygen Devices
Oxygen Concentrators
Portable Oxygen Concentrators
Liquid Portable Oxygen
Oral Appliances
Adaptive Servo Ventilation (ASV) Devices
Masks and Accessories
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
Small Molecule Drug Discovery Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The global small molecule drug discovery market was valued at USD 29,363.85 million in 2018, and is estimated to be valued at USD 46,882.22 million in 2024, witnessing a CAGR of 8.11%. The increasing applications of small molecule drugs for the treatment of chronic diseases are leading to the increased demand for these drugs in the market. Moreover, due to the aforementioned factors, small molecule drugs dominate the biologics in the current healthcare market. The preference of small molecules, along with the increasing disease complications and technological advancements, has led major players to increase their R&D expenditure, which is further acting as the major growth driver for the global small molecule drug discovery market.
The global small molecule drug discovery market is subject to impacts from political situations. The policy implemented by the government has the capability to either amplify or diminish the market.
Scope of the Report
This report estimates the global small molecule drug discovery market. It includes the detailed analysis of small molecules that are in the drug discovery phase only and does not include any other products.
Key Market Trends
Lead Optimization is Expected to hold its Highest Market Share in the Process/Phase Segment
In the process/phase segment of the market, lead optimization is believed to have the largest market size and is expected to witness a CAGR of 7.93% during the forecast period.
The process of lead optimization is achieved by modifying the selected small molecule, in order to improve efficacy and therapeutic value. Once the pharmacophore, which consists of relevant groups on a molecule that interact with a receptor and are responsible for the biological activity, is identified, it is subjected to functional group modification. Various changes are made to the initial compound and the therapeutic index is measured.
Rapid usage of in-vitro experiments, accompanied with computation procedures in early drug discovery for selection of compounds with more promising ADME, i.e., absorption, distribution, metabolism, and excretion, and toxicological profiles, is expected to drive the market studied.
The rise in cancer and other neglected diseases is encouraging investments in lead optimization for enhanced therapeutic value, in order to provide patients with efficient and targeted therapies.
North America Dominates the Market and is Expected to follow the Same Trend in the Forecast Period
North America currently dominates the market for small molecule drug discovery and is expected to continue its stronghold for a few more years. According to FDA, in 2016, the Center for Drug Evaluation and Research (CDER) approved 22 novel drugs, either as new molecular entities (NMEs) under New Drug Applications (NDAs) or as new therapeutic biologics under Biologics License Applications (BLAs). Overall, 31,468 patients participated in these trials. This shows that the United States is focusing on R&D activities to meet the increasing demands of its citizens for better and effective drugs.
The rising focus on the R&D in the country is expected to propel the market growth in the future.
Competitive Landscape
The small molecule drug discovery market is moderately competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancements and product innovations, mid-size to smaller companies are increasing their market presence by introducing new ingredients with fewer prices. Companies, like Pfizer Inc., Bristol-Myers Squibb Company, Merck & Co., Boehringer Ingelheim GmbH, and GlaxoSmithKline, hold the substantial share in the market.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Demand for Small Molecule Drugs
4.2.2 Dominance of Small Molecules in the Market
4.2.3 Increasing Number of Contract Organizations for R&D
4.2.4 Small Molecules in Treatment of Chronic Diseases
4.2.5 High R&D Expenditure in Small Molecule Drugs
4.3 Market Restraints
4.3.1 High Drug Development Cost
4.3.2 Strict Regulations
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Therapeutic Area
5.1.1 Oncology
5.1.2 Central Nervous System
5.1.3 Cardiovascular
5.1.4 Respiratory
5.1.5 Metabolic Disorders
5.1.6 Gastrointestinal
5.1.7 Orthopedics
5.1.8 Anti-infective
5.1.9 Dermatology
5.1.10 Immunology
5.1.11 Other Therapeutic Areas
5.2 By Process/Phase
5.2.1 Target Id/Validation
5.2.2 Hit Generation and Selection
5.2.3 Lead Identification
5.2.4 Lead Optimization
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East & Africa
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East & Africa
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer Inc.
6.1.2 Bristol-Myers Squibb Company
6.1.3 Merck & Co.
6.1.4 Boehringer Ingelheim GmbH
6.1.5 GlaxoSmithKline PLC
6.1.6 AstraZeneca
6.1.7 Johnson & Johnson
6.1.8 Gilead Sciences Inc.
6.1.9 Teva Pharmaceuticals
6.1.10 Teva Pharmaceutical Industries Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Therapeutic Area
Oncology
Central Nervous System
Cardiovascular
Respiratory
Metabolic Disorders
Gastrointestinal
Orthopedics
Anti-infective
Dermatology
Immunology
Other Therapeutic Areas
By Process/Phase
Target Id/Validation
Hit Generation and Selection
Lead Identification
Lead Optimization
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America
Sodium-dependent Glucose Co-transporter 2 (SGLT 2) Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 100 pages | Published: 12-06-2019 |
- Healthcare
- Mordor Intelligence
- 100 pages
- Published: 12-06-2019
Market Overview
The SGLT2 inhibitors class of drugs include Jardiance, Fraxiga, Inovokana, and Suglat, among others. The demand for SGLT2 is expected to grow immensely, due to drugs like Jardiance and Farxiga.
The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. The global SGLT2 market has a high potential for growth, due to the increasing number of diabetic patients and their need for drugs that help reduce high blood glucose levels, despite being on a medication regimen, such as metformin and insulin. SGLT2 serves this specific purpose.
The global market for SGLT2 is worth USD 6,573.8 million in 2019 and is expected to grow at CAGR of 16% by 2024.
Scope of the Report
The report includes a complete study of SGLT2 inhibitors, which include Invokana, Jardiance, Farxiga, and Suglat. The study is further divided into regional- and country-wise analyses, which cover all the drugs in the SGLT2 class.
Key Market Trends –
Jardiance is Leading the SGLT2 Market.
Jardiance, which was released globally in 2014, is a once-daily oral medication that is used to control blood glucose levels in people with type-2 diabetes.
Jardince is gaining sales when compared to Invokana, with patients preferring this drug, as it has a lower risk of cardiovascular diseases when compared to other SGLT2 drugs, by helping the kidneys remove glucose from the bloodstream.
Jardiance accounted for 41.5% of the sales in the global SGLT2 class of drugs in 2017. The market for Jardince was worth USD 2.5 billion in 2018 and is expected to grow at a CAGR of 15.78%, during the forecast period (2019-2024).
65% of the Market Share is Occupied by North America.
The growing global type-2 diabetes population promotes the growth of SGLT2 drugs. North America accounts for the highest type- 2 diabetic population. Prices are comparatively high in this region.
The North America SGLT2 market accounts for USD 3,471.5 million in 2018 and is expected to grow at CAGR of 15.5% by 2024.
In the United States, there are close to 900 lawsuits currently pending, regarding Invokana. Jardiance holds 50% of the market share in the US SGLT2 market.
Competitive Landscape
The SGLT2 market is highly consolidated, with a few significant manufacturers having a global market presence.
The joint ventures that occurred between players in the recent past have helped the companies strengthen their market presence. For example, Eli Lilly and Boehringer Ingelheim make Jardiance together, which is a very popular SGLT2 class drug.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Drivers
4.3 Restraints
4.4 Porter’s Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Drug
5.1.1 Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
5.1.1.1 Invokana (Canagliflozin)
5.1.1.2 Jardiance (Empagliflozin)
5.1.1.3 Farxiga/Forxiga (Dapagliflozin)
5.1.1.4 Suglat (Ipragliflozin)
5.2 Geography
5.2.1 North America
5.2.1.1 United States (Value and Volume 2012-2024)
5.2.1.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.1.2 Canada (Value and Volume 2012-2024)
5.2.1.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.1.3 Rest of North America (Value and Volume 2012-2024)
5.2.1.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2 Europe
5.2.2.1 France (Value and Volume 2012-2024)
5.2.2.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.2 Germany (Value and Volume 2012-2024)
5.2.2.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.3 Italy (Value and Volume 2012-2024)
5.2.2.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.4 Spain (Value and Volume 2012-2024)
5.2.2.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.5 UK (Value and Volume 2012-2024)
5.2.2.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.6 Russia (Value and Volume 2012-2024)
5.2.2.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.2.7 Rest of Europe (Value and Volume 2012-2024)
5.2.2.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3 Latin America
5.2.3.1 Mexico (Value and Volume 2012-2024)
5.2.3.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3.2 Brazil (Value and Volume 2012-2024)
5.2.3.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.3.3 Rest of Latin America (Value and Volume 2012-2024)
5.2.3.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4 Asia-Pacific
5.2.4.1 Japan (Value and Volume 2012-2024)
5.2.4.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.2 South Korea (Value and Volume 2012-2024)
5.2.4.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.3 China (Value and Volume 2012-2024)
5.2.4.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.4 India (Value and Volume 2012-2024)
5.2.4.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.5 Australia (Value and Volume 2012-2024)
5.2.4.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.6 Vietnam (Value and Volume 2012-2024)
5.2.4.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.7 Malaysia (Value and Volume 2012-2024)
5.2.4.7.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.8 Indonesia (Value and Volume 2012-2024)
5.2.4.8.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.9 Philippines (Value and Volume 2012-2024)
5.2.4.9.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.10 Thailand (Value and Volume 2012-2024)
5.2.4.10.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.4.11 Rest of Asia-Pacific (Value and Volume 2012-2024)
5.2.4.11.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5 Middle East & Africa
5.2.5.1 Saudi Arabia (Value and Volume 2012-2024)
5.2.5.1.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.2 Iran (Value and Volume 2012-2024)
5.2.5.2.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.3 Egypt (Value and Volume 2012-2024)
5.2.5.3.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.4 Oman (Value and Volume 2012-2024)
5.2.5.4.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.5 South Africa (Value and Volume 2012-2024)
5.2.5.5.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
5.2.5.6 Rest of Middle & Africa (Value and Volume 2012-2024)
5.2.5.6.1 By Drug (Invokana, Jardiance, Farxiga, Suglat)
6 MARKET INDICATORS
6.1 Type-1 Diabetes Population (2012-2024)
6.2 Type-2 Diabetes Population (2012-2024)
7 COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Eli Lilly
7.1.2 Janssen Pharmaceuticals
7.1.3 Astellas
7.1.4 Boehringer Ingelheim
7.1.5 AstraZeneca
7.1.6 Bristol Myers Squibb
7.2 MARKET SHARE ANALYSIS
7.2.1 Eli Lilly
7.2.2 Janssen Pharmaceuticals
7.2.3 Astellas
7.2.4 Boehringer Ingelheim
7.2.5 AstraZeneca
8 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Drug
Sodium – Glucose Cotransport -2 (SGLT-2) Inhibitor (Value and Volume 2012-2024)
Invokana (Canagliflozin)
Jardiance (Empagliflozin)
Farxiga/Forxiga (Dapagliflozin)
Suglat (Ipragliflozin)
Geography
North America
United States (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Canada (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of North America (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Europe
France (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Germany (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Italy (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Spain (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
UK (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Russia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Europe (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Latin America
Mexico (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Brazil (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Latin America (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Asia-Pacific
Japan (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Korea (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
China (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
India (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Australia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Vietnam (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Malaysia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Indonesia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Philippines (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Thailand (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Asia-Pacific (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Middle East & Africa
Saudi Arabia (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Iran (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Egypt (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Oman (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Africa (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
Rest of Middle & Africa (Value and Volume 2012-2024)
By Drug (Invokana, Jardiance, Farxiga, Suglat)
South Africa Minimally Invasive Surgical Devices Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 74 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 74 pages
- Published: 07-06-2019
Market Overview
The major factors for the growth of the South African minimally invasive surgical devices market include the higher acceptance rate of minimally invasive procedures over traditional procedures, improved patient quality of life and increasing number of surgeries among the aging population, minimally invasive surgeries help reduce healthcare costs and time, and increasing prevalence of lifestyle-related and chronic disorders.
Minimally invasive surgeries (MIS) have been reported to cause less post-operative pain, and hence, patients receive smaller dosages of painkillers. As there are minimal cuts or stitches involved, the hospital stay is relatively shorter, and patients need not visit the hospital frequently. Traditional open surgeries involve long incisions made through the muscles, and these muscles take a considerable amount of time to heal, whereas MIS procedures involve smaller incisions, leading to quicker recovery. In addition, the body scars involved in MIS are barely noticeable. The main advantage that MIS has over traditional open surgeries is higher precision, due to video-assisted equipment, which produces a better and magnified image of the organs or body parts being operated. These surgeries are gaining wider acceptance among the geriatric population, due to the relatively shorter recovery time. These developments have created significant traction for robotic surgeries in several private hospitals in South Africa. Most of the initial surgeries performed using these robotic systems were to treat cardiovascular, urology, and neurology conditions. Furthermore, with improvements in the reimbursement scenario and streamlining of regulatory guidelines, the MIS devices market is expected to grow significantly over the forecast period.
In South Africa, NCDs (non-communicable diseases) account for 84% of all deaths in persons aged 60 years and above, with ischemic heart disease and stroke being the leading single causes of death in men. The order is reversed in women. Together the diseases account for about one-third of the total deaths. COPD accounts for almost double the number of deaths among men than women. Malignant neoplasms are responsible for 16% of deaths in older men and 10% in older women, with lung cancer as a predominant cause in men and breast cancer in women. Thus, the rising aging population, coupled with the increase in prevalence of various chronic conditions, such as cardiovascular disease, GI diseases, cancer, and NCD’s, is expected to drive the market over the forecast period.
Scope of the Report
As per the scope of this report, minimally invasive surgical devices refer to electrosurgical systems, robot-assisted surgical systems, and surgical equipment, such as needles, retractors, and guide wires, which are used during the minimally invasive procedure.
Key Market Trends
Trocars is the Segment by Surgical Equipment that is Expected to Grow the Fastest During the Forecast Period
The earlier usage of trocars was specifically for the drainage of infected body fluid and gases from the body, but with later innovations, urologists started using trocars for the easy insertion of the surgical scopes inside the body. Currently, trocars are majorly used for laparoscopic procedures, which are associated with the abdominal surgeries that are also referred to as open surgeries. These procedures are made easy with the revolutionary implementation of trocars, which has contributed to the improvement of patient care. Increasing number of laparoscopic surgeries, along with the significance of trocars, is the factor contributing to the growth of this segment in South Africa.
Competitive Landscape
The South African minimally invasive surgical devices market is dominated by few global players. These global enterprises are already competitors in the developed regions, and in South Africa, they operate through regional offices or a network of distributors. In the South African market, which is currently categorized by the presence of high growth opportunities, the existing players are competing with each other on various fronts, such as the introduction of new products, increasing geographical penetration, enhancing distribution channel. The high competition is expected to drive the merger and acquisition activity, thereby, leading to medium market consolidation in few business segments.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Higher Acceptance Rate of Minimally Invasive Procedures Over Traditional Procedures
4.2.2 Improved Patient Quality of Life and Increasing Number of Surgeries Among the Aging Population
4.2.3 Minimally Invasive Surgeries Help Reduce Healthcare Costs and Time
4.2.4 Increasing Prevalence of Lifestyle-related and Chronic Disorders
4.3 Market Restraints
4.3.1 Shortage of Experienced Professionals
4.3.2 Stringent Regulatory Framework and Insurance Plans for Medical Devices are Restraining the Market
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 Product Type
5.1.1 Surgical Equipment
5.1.1.1 Catheters
5.1.1.2 Staplers
5.1.1.3 Cannula
5.1.1.4 Guide Wires
5.1.1.5 Retractors
5.1.1.6 Needles
5.1.1.7 Trocars
5.1.1.8 Forceps
5.1.1.9 Metal Shafts
5.1.1.10 Other Surgical Instruments and Accessories
5.1.2 Electrosurgical Systems
5.1.2.1 Electrosurgical Accessories
5.1.2.2 Suction Coagulators
5.1.2.3 Pencils
5.1.2.4 Electrodes
5.1.2.5 Bipolar Forceps
5.1.3 Robot-assisted Surgical Systems
5.1.3.1 Da Vinci Systems
5.1.3.2 Zeus Robotic Surgical Systems
5.1.3.3 Other Robot-assisted Surgical Systems
5.1.4 Monitoring and Visualization Equipment
5.1.4.1 MRI Scanners
5.1.4.2 CT Scanners
5.1.4.3 X-ray Equipment
5.1.4.4 Ultrasound Equipment
5.1.4.5 Surgical Visualization Equipment
5.2 By Technology
5.2.1 Laparoscopy
5.2.2 Endoscopy
5.2.3 Arthroscopic Techniques
5.2.4 Ablative Techniques
5.2.4.1 Cryoablation
5.2.4.2 Radio Frequency Ablation
5.2.4.3 Microwave Ablation
5.2.4.4 Embolization
5.2.4.5 Irreversible Electroporation
5.3 By Application
5.3.1 Cardiac Surgery
5.3.2 Urology
5.3.3 Neurosurgery
5.3.4 Gastrointestinal Surgery
5.3.5 Orthopedic
5.3.6 Gynecologic Surgery
5.3.7 Colorectal Surgery
5.3.8 Weight Loss
5.3.9 Lung & Respiratory Care
5.3.10 Ophthalmology
5.3.11 ENT Surgery
5.3.12 Dermatological Surgery
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 GE Healthcare
6.1.3 Intuitive Surgical
6.1.4 Johnson & Johnson
6.1.5 Medtronic PLC
6.1.6 Koninklijke Philips NV
6.1.7 Siemens
6.1.8 Smith & Nephew
6.1.9 Stryker Corporation
6.1.10 Zimmer Biomet
6.1.11 Applied Medical Resources Corporation
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
Product Type
Surgical Equipment
Catheters
Staplers
Cannula
Guide Wires
Retractors
Needles
Trocars
Forceps
Metal Shafts
Other Surgical Instruments and Accessories
Electrosurgical Systems
Electrosurgical Accessories
Suction Coagulators
Pencils
Electrodes
Bipolar Forceps
Robot-assisted Surgical Systems
Da Vinci Systems
Zeus Robotic Surgical Systems
Other Robot-assisted Surgical Systems
Monitoring and Visualization Equipment
MRI Scanners
CT Scanners
X-ray Equipment
Ultrasound Equipment
Surgical Visualization Equipment
By Technology
Laparoscopy
Endoscopy
Arthroscopic Techniques
Ablative Techniques
Cryoablation
Radio Frequency Ablation
Microwave Ablation
Embolization
Irreversible Electroporation
By Application
Cardiac Surgery
Urology
Neurosurgery
Gastrointestinal Surgery
Orthopedic
Gynecologic Surgery
Colorectal Surgery
Weight Loss
Lung & Respiratory Care
Ophthalmology
ENT Surgery
Dermatological Surgery
Spain In-Vitro Diagnostics Market- Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 62 pages | Published: 13-06-2019 |
- Healthcare
- Mordor Intelligence
- 62 pages
- Published: 13-06-2019
Market Overview
The key factors propelling the growth of the Spanish in vitro diagnostics market is the high prevalence of chronic diseases, increasing use of point-of-care (POC) diagnostics, and advanced technologies.
The increasing incidences of chronic and infectious diseases and a rapidly evolving healthcare environment are expected to drive the Spanish in vitro diagnostics market in the years to come. They account for the majority of hospital admissions and prescriptions filling. They are also a major reason for physician visits. These diseases account for the vast majority of healthcare spending. Hence, the high prevalence of chronic diseases in the country is the primary factor responsible for the growth of the IVD market in Spain.
Owing to the ease of use and ability to provide instant results, combined with ease of procurement, the use of POC diagnostics in Spain is increasing rapidly, and this, in turn, is promoting the growth of the IVD market in the country. POC technologies form an influential driver for the market.
In addition, rapid advancements in the technology and increasing adoption toward novel technologies are the other factors contributing to the growth of the IVD market in the country.
Scope of the Report
As per the scope of the report, in vitro diagnostics involves the medical devices and consumables that are utilized to perform in vitro tests on various biological samples. These tests are done on samples, such as blood or tissue that have been taken from the human body. In vitro diagnostics can detect diseases or other conditions, and can be used to monitor a person’s overall health to cure, treat, or prevent diseases.
Key Market Trends
POC Diagnostics Holds the Largest Share in the by Technique Segment
The POC diagnostics segment is increasing due to factors, such as the rising prevalence of chronic and infectious diseases, private investments, and venture capital activities supporting R&D of novel products, which are expected to boost the market growth. In addition, rapid advancements in POC technology and increasing adoption toward novel technologies are the other factors contributing to the growth of the IVD market in the country.
Competitive Landscape
The companies are found focusing on increasing technological advancements in order to address customer needs, like fully automated systems that save manual processes and consumables. Manual processes also provide fast and accurate results. In addition, all the major IVD companies have launched new products for strengthening their diagnostic capabilities.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Advanced Technologies
4.3 Market Restraints
4.3.1 Stringent Regulations
4.3.2 Unclear Reimbursement Policies
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technique
5.1.1 Immunochemistry
5.1.2 POC Diagnostics
5.1.3 Molecular Diagnostics
5.1.4 Hematology
5.1.5 Tissue Diagnostics
5.1.6 Microbiology
5.1.7 Self-blood Glucose Monitoring
5.1.8 Other Techniques
5.2 By Product
5.2.1 Instrument
5.2.2 Reagent
5.2.3 Data Management System
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.2 Diabetes
5.4.3 Cancer/Oncology
5.4.4 Cardiology
5.4.5 Autoimmune Disease
5.4.6 Nephrology
5.4.7 Drug Testing
5.4.8 HIV/AIDS
5.4.9 Other Applications
5.5 By End Users
5.5.1 Laboratory
5.5.2 Hospital
5.5.3 Academia
5.5.4 POC Testing
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 bioMerieux SA
6.1.2 Danaher Corporation
6.1.3 F. Hoffmann-La Roche AG
6.1.4 Becton, Dickinson and Company
6.1.5 Bio-Rad Laboratories Inc.
6.1.6 Abbott Laboratories
6.1.7 Arkray Inc.
6.1.8 Sysmex Corporation
6.1.9 Ortho Clinical Diagnostics
6.1.10 Siemens Healthcare GmbH
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Technique
Immunochemistry
POC Diagnostics
Molecular Diagnostics
Hematology
Tissue Diagnostics
Microbiology
Self-blood Glucose Monitoring
Other Techniques
By Product
Instrument
Reagent
Data Management System
By Usability
Disposable IVD Devices
Reusable IVD Devices
By Application
Infectious Disease
Diabetes
Cancer/Oncology
Cardiology
Autoimmune Disease
Nephrology
Drug Testing
HIV/AIDS
Other Applications
By End Users
Laboratory
Hospital
Academia
POC Testing
Spectacle Lens Market – Growth, Trends, and Forecast (2019 – 2024)
| Healthcare | Published by: Mordor Intelligence | Market: |
| 115 pages | Published: 07-06-2019 |
- Healthcare
- Mordor Intelligence
- 115 pages
- Published: 07-06-2019
Market Overview
The growth of the global spectacle lens market is due to the increasing geriatric population and rising prevalence of optical disorders. Globally, the percentathe ge of elderly population increased from 5.6% to 8.6% between 1961 and 2011. According to the US Census Bureau’s Statistics, among 7.3 billion people in the world, in 2015 an estimated 8.5 %, or 617.1 million, were aged 65 years and older.
According to the WHO, currently, people have high life expectancy. By 2050, the world’s population aged 60 years and above is expected to reach a total of 2 billion. As of 2018, 125 million people are aged 80 years or older. As per the same source, by 2050, it is estimated that almost 120 million people will be living in China alone. The increase in the number of cases of ocular conditions, such as cataract and diabetic retinopathy, across the world, is assisting the market growth. According to the National Eye Institute, the United States recorded 7.7 million diabetic retinopathy cases and 24 million cataract cases, which are expected to reach 11.3 million and 38 million, respectively, by 2030. Hence, these factors are expected to propell the market growth over the forecast period.
Scope of the Report
This report includes an in-depth study of the global spectacle lens market (henceforth, referred to as the market studied’). As per the scope of the report, the spectacle lens is the corrective lens, which is used to correct eye problems and improve vision. Common indications of the use of spectacle lens include myopia, astigmatism, presbyopia, and hypermetropia.
Key Market Trends
Prescription Glass Segment is Expected to Exhibit Fastest Growth Rate over the Forecast Period
Prescription glasses refer to spectacles whose lenses have been made specifically to match the wearer’s defects of vision. According to a report published by the Vision Council of America, in 2015, 76.2% of American adults used vision correction. The report also states that 159.2 million people in the United States used prescription eyeglasses as a means of vision correction. In addition, on the basis of gender, 61.2% men in the United States used eyeglasses whereas 67.3% of women used prescription glasses (2015).
The price of prescription glasses generally ranges between USD 5-USD 30. It depends upon various factors, such as frame type, frame size, gender, material, weight, and prescription-type (single vision, bifocal, etc.). Some of the brands for prescription glasses include Vincent Chase, John Jacobs, Ray-Ban, Tom Ford, Persol, Calvin Klein, etc., which hold a major share of the prescription glass market.
North America Captured the Largest Market Share and is Expected to Retain its Dominance
North America dominated the overall spectacle lens market, owing to the speedy adoption of spectacles for vision care in the region, growing geriatric population, and increasing awareness. The United States accounted to be the major contributor to the North American spectacle lens market. The Vision Council of America reported that there were 188.7 million Americans wearing some form of vision correction in the country, which was just over 3 out of every 4 adults (as in 2015). Moreover, according to the Vision Council of America, the usage increased the most for OTC readers (from 29.8 million in 2014 to 30.9 million in 2015) and Rx sunglasses (from 27.4 million in 2014, to 29.1 million in 2015). In addition, the usage of prescription glasses increased from 156.5 million in 2014 to 159.2 million in 2015 in the country. Thus, all the aforementioned factors are expected to propel the growth of the US spectacle lens market.
Competitive Landscape
The spectacle lens market is highly competitive and consists of several major players. In terms of market share, few of these major players currently dominate the market. The presence of major market players, such as Carl Zeiss Meditec AG, Essilor International SA, Hoya Vision Care Company, Vision Ease, and Seiko Optical Products Co. Ltd is, in turn, increasing the overall competitive rivalry of the market. The product advancements and improvement in the spectacle lens market by the major players is increasing the competitive rivalry.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– Report customization as per the client’s requirements
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Aging Population
4.2.2 Increasing Prevalence of Optical Disorders
4.3 Market Restraints
4.3.1 Poor Quality of Lens
4.4 Industry Attractiveness Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Type
5.1.1 Single Vision
5.1.2 Bifocal
5.1.3 Trifocal
5.1.4 Progressive
5.2 By Coating Type
5.2.1 Anti-reflective Coating
5.2.2 Scratch-resistant Coating
5.2.3 Anti-fog Coating
5.2.4 UV Protection
5.2.5 Other Coatings
5.3 By Usage
5.3.1 Prescription Glass
5.3.2 OTC Reading Glass
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 United Kingdom
5.4.2.2 Germany
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East & Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East & Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Carl Zeiss Meditec AG
6.1.2 Essilor International SA
6.1.3 Hoya Vision Care Company
6.1.4 Vision Ease
6.1.5 Seiko Optical Products Co. Ltd
6.1.6 Rodenstock GmbH
6.1.7 GKB Ophthalmics Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS
MARKET SEGMENTATION
By Type
Single Vision
Bifocal
Trifocal
Progressive
By Coating Type
Anti-reflective Coating
Scratch-resistant Coating
Anti-fog Coating
UV Protection
Other Coatings
By Usage
Prescription Glass
OTC Reading Glass
Geography
North America
United States
Canada
Mexico
Europe
United Kingdom
Germany
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America